Soleno Therapeutics Inc Cash Flow Quality Index

Latest as of March 2026: 0.83x

Soleno Therapeutics Inc cash flow quality index. Soleno Therapeutics Inc (SLNO) has a Cash Flow Quality Index of 0.83x as of March 2026. Operating cash flow of $25.98 Million is below net income of $31.38 Million, suggesting accrual-heavy earnings not yet converted to cash. See Soleno Therapeutics Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.

Cash Flow Quality Index

0.83x

Operating CF / Net Income

Operating Cash Flow

$25.98 Million

USD

Net Income

$31.38 Million

USD

Data as of

Mar 2026

Most recent filing

Cash Flow Quality Index of Soleno Therapeutics Inc (2025–2025)

Cash flow quality index of Soleno Therapeutics Inc from 2025 to 2025. Historical Cash Flow Quality Index for Soleno Therapeutics Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore how well can Soleno Therapeutics Inc service its debt to assess how comfortably operating cash covers total debt obligations.

Soleno Therapeutics Inc Cash Flow Quality Index by Year (2025–2025)

Soleno Therapeutics Inc cash flow quality index by year from 2025 to 2025. Year-by-year earnings quality comparison for Soleno Therapeutics Inc. For the full cash flow conversion analysis, see Soleno Therapeutics Inc cash flow conversion.

Year	Quality Index	Operating CF (USD)	Net Income	YoY Change
2025	2.24x	$46.80 Million	$20.89 Million	—

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.